Descriptive profile of PIK3CA-mutated colorectal cancer in postmenopausal women

被引：0
|
作者：
Amanda I. Phipps
Karen W. Makar
Polly A. Newcomb
机构：
[1] Fred Hutchinson Cancer Research Center,Public Health Sciences Division
[2] Fred Hutchinson Cancer Research Center,Public Health Sciences Division
来源：
International Journal of Colorectal Disease | 2013年 / 28卷
关键词：
Colorectal cancer; PIK3CA; Survival; KRAS;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1637 / 1642
页数：5
相关论文
共 50 条
  • [41] Anticancer effects of alpelisib on PIK3CA-mutated canine mammary tumor cell lines
    Yeom, Jiah
    Cho, Yoonju
    Ahn, Seoungyob
    Jeung, Soyoung
    FRONTIERS IN VETERINARY SCIENCE, 2023, 10
  • [42] Network Analysis Reveals A Signaling Regulatory Loop in PIK3CA-mutated Breast Cancer Predicting Survival Outcome
    McGee, Shauna R.
    Tibiche, Chabane
    Trifiro, Mark
    Wang, Edwin
    GENOMICS PROTEOMICS & BIOINFORMATICS, 2017, 15 (02) : 121 - 129
  • [43] Next-Generation Sequencing-Based Analysis of Clinical and Pathological Features of PIK3CA-Mutated Breast Cancer
    Smok-Kalwat, Jolanta
    Chmielewski, Grzegorz
    Stando, Rafal
    Sadowski, Jacek
    Macek, Pawel
    Kowalik, Artur
    Nowak-Ozimek, Ewelina
    Gozdz, Stanislaw
    DIAGNOSTICS, 2023, 13 (18)
  • [44] Correlation between circulating cell-free PIK3CA tumor DNA levels and treatment response in patients with PIK3CA-mutated metastatic breast cancer
    Kodahl, Annette R.
    Ehmsen, Sidse
    Pallisgaard, Niels
    Jylling, Anne M. B.
    Jensen, Jeanette D.
    Laenkholm, Anne-Vibeke
    Knoop, Ann S.
    Ditzel, Henrik J.
    MOLECULAR ONCOLOGY, 2018, 12 (06): : 925 - 935
  • [45] In vitro anticancer effects of alpelisib against PIK3CA-mutated canine hemangiosarcoma cell lines
    Maeda, Marika
    Ochiai, Kazuhiko
    Michishita, Masaki
    Morimatsu, Masami
    Sakai, Hiroki
    Kinoshita, Nayuta
    Sakaue, Motoharu
    Onozawa, Eri
    Azakami, Daigo
    Yamamoto, Masami
    Ishioka, Katsumi
    Sadahira, Takuya
    Watanabe, Masami
    Tanaka, Yoshikazu
    ONCOLOGY REPORTS, 2022, 47 (04)
  • [46] PIK3CA in colorectal cancer
    Cathomas, Gieri
    FRONTIERS IN ONCOLOGY, 2014, 4
  • [47] Alpelisib in the treatment of metastatic PIK3CA-mutated breast cancer: final analysis of overall survival in the SOLAR-1 study
    Matlac, Dieter M.
    Krawczyk, Natalia
    Hanker, Lars
    Rody, Achim
    Banys-Paluchowski, Maggie
    ONKOLOGE, 2021, 27 (09): : 936 - 940
  • [48] The way to precision medicine in gynecologic cancers: The first case report of an exceptional response to alpelisib in a PIK3CA-mutated endometrial cancer
    Passarelli, Anna
    Ventriglia, Jole
    Pisano, Carmela
    Cecere, Sabrina Chiara
    Di Napoli, Marilena
    Rossetti, Sabrina
    Tambaro, Rosa
    Tarotto, Luca
    Fiore, Francesco
    Farolfi, Alberto
    Bartoletti, Michele
    Pignata, Sandro
    FRONTIERS IN ONCOLOGY, 2023, 12
  • [49] Alpelisib for the treatment of PIK3CA-mutated, hormone receptor-positive, HER2-negative metastatic breast cancer
    Leenhardt, Fanny
    Alexandre, Marie
    Jacot, William
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (06) : 667 - 675
  • [50] PI3Kα-specific inhibitor BYL-719 synergizes with cisplatin in vitro in PIK3CA-mutated ovarian cancer cells
    Thibault, Benoit
    Thole, Adrien
    D'Angelo, Romina
    Basset, Celine
    Guillermet-Guibert, Julie
    SCIENTIFIC REPORTS, 2025, 15 (01):
12345